New multiple myeloma drug trial halted early

NCT ID NCT04123418

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new drug called WVT078, alone or with another drug (WHG626), in 56 people with multiple myeloma that returned or didn't respond to at least two prior treatments. The main goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA (MM)

Contacts and locations

Locations

Emory University School of Medicine-Winship Cancer Institute

Atlanta, Georgia, 30322, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Novartis Investigative Site

Melbourne, Victoria, 3004, Australia
Novartis Investigative Site

Dresden, 01307, Germany
Novartis Investigative Site

Heidelberg, 69120, Germany
Novartis Investigative Site

Tel Aviv, 6423906, Israel
Novartis Investigative Site

Milan, MI, 20162, Italy
Novartis Investigative Site

Bunkyo Ku, Tokyo, 113-8677, Japan
Novartis Investigative Site

Oslo, NO-0407, Norway
Novartis Investigative Site

Santander, Cantabria, 39008, Spain
Novartis Investigative Site

Barcelona, 08041, Spain
University Of Wisconsin

Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.